Uchechukwu (Uche) Sampson Email & Phone Number

The Medical Advisory Board oversees ADI’s Healthcare and Life Sciences program that provides strategy and business development services to many corporations including publicly traded companies. ADI provides a comprehensive array of services, including government relations, program development and execution, business development, and strategic consulting. The team at ADI includes former senior government officials, military officers, and congressional aides who collaborate with a single goal — to provide outcomes that add to the success of our clients. Whether it’s crafting a government affairs strategy, getting a message out to key decision makers and opinion leaders, or marketing a product or service to the federal government, ADI offers unmatched knowledge, expertise and quality service.

Chicago, Illinois, United States

The advisory board supports Birthways effort to develop a tech-enabled marketplace platform for optimal delivery of doula services for labor and postpartum support across the United States.

Strategy and plan for healthcare portfolio development including identifying potential targets for acquisition, preliminary due diligence, as well as valuation and proforma development. ECD (Economic and Community Development) is a start-up private equity firm focused on producing the highest quality results for partners by investing in sustainable and socially impactful projects.

Lead personnel for scientific and strategic business oversight required for asset purchase negotiations.

Business and research strategies for development and commercialization of rapid vertical flow diagnostic tests for COVID-19 disease. Webb Diagnostic Technologies is a start-up Biotech Company focused on developing point-of-care antibody testing for SARS-CoV-2, the virus that causes COVID-19 disease.

Co-led scientific due diligence for the asset acquisition that led to the founding of Micelle Biopharma. Also, co-led the early strategic visioning, pitch deck preparation, financial models, and investment proforma with exit valuation. Oversaw the clinical program, which included an on-going Phase 2 trial open-label extension arm, planning and protocol development for a pivotal Phase 3 clinical trial, FDA communications, interaction with clinical research organizations (CRO) and data safety monitoring board (DSMB), budgeting, personnel oversight, other executive engagements. Micelle BioPharma, Inc. is an integrated pharmaceutical company that focuses on developing and marketing a variety of products, including those based on the proprietary unique drug delivery systems designed to improve the body’s ability to absorb and use lipophilic compounds such as fatty acids, hormones, several vitamins, and many active pharmaceutical ingredients.

The Center for Translation Research and Implementation Science (CTRIS) branch supported and fostered healthcare service delivery innovation by developing initiatives to improve our understanding of the health system levers that can be modulated to improve multi-level (patient, provider, and health system) outcomes. I led development of various initiatives, organized and moderated multiple workshops and Think Tank meetings as well as led dissemination of reports through manuscripts and publications. Key NIH Accomplishments: Co-led the development of research portfolio of over $200 million. Recipient of four NHLBI Director’s Awards for leadership activities and served on the Small Business Advisory Committee of the NHLBI, which facilitates the use of congressionally mandated funds for Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program by identifying, assessing, and developing ideas for commercial development.

In addition to clinical duties, mentoring responsibilities, and assigned ad hoc administrative and leadership duties, my major academic research efforts centered on developing a synergistic platform for translational, clinical, and epidemiologic studies. Basic science: Validation of noninvasive imaging methods for in vivo assessment and measurement of aneurysmal aorta, aneurysmal wall inflammation, and associated molecular mechanisms. Successfully reported the quantitative estimates of variability of in vivo sonographic measurements of mouse aorta relevant for translational research studies of abdominal aortic aneurysms and related arterial diseases. Characterized in detail the temporal evolution of aneurysms in mice and the role of oxidant stress.Translational/Clinical: Conducted a pilot study that employed flourodeoxyglucose (FDG) positron emission tomography (PET) imaging co-registered with structural computerized tomography (CT) images for the in vivo localization and quantification of vascular inflammation in patients with AAA in order to determine whether increased inflammation within the walls of the aneurysm correlates with risk of adverse outcome. The successful pilot study led to a VA Merit Review Proposal Award for a 2 center study within the VA Health System. Epidemiology/population research: I served on the cardiovascular disease expert group for PAD and AAA in the Global Burden of Disease (GBD) 2010 Study. In my role, I led the systematic reviews, data extraction, and analysis of the work on PAD and aortic aneurysms which led to major publications in the Lancet and Global Heart Journal. Additionally, I led a collaborative group of investigators at Vanderbilt University Medical Center, Meharry Medical College, and Tennessee State University that utilized the Tennessee Hospital Discharge Data System (HDDS) and the Southern Community Cohort Study (SCCS) as platforms for Cardiovascular Studies.

Clinical training in cardiovascular medicineResearch Fellowship:• Focus area under mentors Valentina Kon, MD and Sergio Fazio, MD, PhD: Laboratory evaluation of the pathobiology of abdominal aortic aneurysms in Apo E-/- mice• Focus area under mentor John C. Gore, PhD: In vivo imaging of abdominal aortic aneurysms in Apo E-/- mice• Focus area under mentor Marvin W. Kronenberg, MD: FDG PET/CT imaging of patients with abdominal aortic aneurysms

Responsibilities included short- and long-term planning, program and staff development, resource and budget management, quality monitoring and improvement, strategic planning, and evaluation of policies and procedures to ensure quality patient care and patient satisfaction. Maintained clinical and management knowledge to advance the profession and utilized team leadership within the department to accomplish these goals. Worked in cooperation and under the direction of the Chief of Cardiology to meet all regulation and accreditation standards. Assumed temporary management responsibility for other clinical areas as needed. Fostered the practice of patient and family centered care in concert with the values and standards of the medical college and hospital.

Cardiovascular Imaging Training.Rubidium PET/CT Imaging, SPECT Imaging, and CT AngiographyBrigham and Women's Hospital, Harvard Medical School, Boston MA (July 2004 to June 2005)Clinical Research Fellow in Medicine:Focus Areas: Clinical trials (SAVE, VALIANT, CHARM); Clinical Endpoints Committees; Echocardiography ResearchBrigham and Women's Hospital, Harvard Medical School, Boston MA (July 2002 to June 2004)

Bowen-Brooks Fellowship of the New York Academy of Medicine

Master Of Science - Ms, Biostatistics

Master Of Science - Ms, Evidence-Based Health Care

Master Of Business Administration - Mba, Health/Health Care Administration/Management

Master Of Public Health - Mph, Health/Health Care Administration/Management

Bachelor Of Medicine, Bachelor Of Surgery - Mbbs, Medicine